ClinicalTrials.Veeva

Menu

The Effectiveness of Nivolumab Monotherapy as First-Line Therapy in Adults With Advanced Melanoma in Germany

Bristol-Myers Squibb (BMS) logo

Bristol-Myers Squibb (BMS)

Status

Withdrawn

Conditions

Melanoma

Treatments

Other: Non-Interventional

Study type

Observational

Funder types

Industry

Identifiers

NCT03205722
CA209-939

Details and patient eligibility

About

A retrospective, observational study based on chart reviews for patients with advanced melanoma treated with nivolumab monotherapy prescribed as first-line therapy between June 2015 and June 2016, conducted in a representative sample of sites in Germany.

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Adult patients with a primary diagnosis of advanced melanoma (histologically confirmed stage III [unresectable] or stage IV skin, ocular, or mucosal melanoma)
  • Newly initiated with nivolumab monotherapy as their first-line therapy for previously untreated advanced melanoma between June 2015 and June 2016
  • At least 18 years of age at time of treatment decision

Exclusion criteria

  • Patients with a current primary diagnosis of a cancer other than advanced melanoma ie, a cancer other than melanoma that requires systemic or other treatment
  • Patients currently included in an interventional clinical trial for his/her locally advanced or metastatic melanoma. Patients who have completed their participation in an interventional trial; or who are not receiving study drug anymore and who are only followed-up for overall survival can be enrolled. In case of a blinded study, the treatment arm (ie, type of administered treatment) needs to be known.
  • Patients < 18 years of age at time of treatment initiation

Other protocol defined inclusion/exclusion criteria could apply

Trial design

0 participants in 1 patient group

Melanoma patients with 1st-line Nivo treatment
Description:
Non-Interventional. Patients with advanced melanoma treated with nivolumab monotherapy prescribed as first-line therapy between June 2015 and June 2016.
Treatment:
Other: Non-Interventional

Trial contacts and locations

0

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems